Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain

Official title

Randomized Controlled Trial of Focused Shockwave, Radial Wave, and Sham Therapy for Erectile Dysfunction and Focused Shockwave and Sham Therapy for Chronic Pelvic Pain Syndrome in Patients With and Without History of Prostate Cancer

Overview

The purpose of this study to perform a randomized, sham controlled analysis of the effectiveness of both fSWT and rWT in the relief of erectile dysfunction and chronic pelvic pain syndrome.

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will undergo screening to determine eligibility for study entry. Participants who meet eligibility requirements will be randomized in a double blind manner (participant and investigator) to each treatment arm depending on their primary complaint. Participants with erectile dysfunction will be randomized 2:2:1 to either fSWT, rWT or sham therapy. Patients with chronic pelvic pain syndrome will be randomized 1:1 to either fSWT with pelvic floor physical therapy (PFPT) or PFPT with sham treatment.

Interventions

• Device Focused shockwave
  Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
• Device Radial wave
  Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
• Device Sham treatment
  Handheld sham probe

Primary outcome measures

• Erectile Dysfunction [Time frame: baseline, 3 and 6 months]
• Chronic Prostatitis/Chronic Pelvic Pain Syndrome: [Time frame: baseline, 3 and 6 months]

Secondary outcome measures (3)

• Erectile Dysfunction [Time frame: baseline, 3 and 6 months]
• Erectile Dysfunction [Time frame: baseline, 3 and 6 months]
• Erectile Dysfunction [Time frame: baseline, 3 and 6 months]

Eligibility criteria

Erectile Dysfunction Group (ED) Inclusion Criteria (ED): (all of the following)

• Cis-gendered heterosexual adult males18 years old
• Stable relationship of more than 3 months duration with currently willing sexual partner and desire for penetration.
• Mild to moderate organic erectile dysfunction (IIEF-EF score 11-25) in the last 3 months
• If ED responsive or partially responsive to current use of PDE5I, participant must be willing to discontinue PDE5I for 4 weeks prior to trial and remain off PDE5I for the duration of the study. Partially responsive ED is defined as inadequate response for desired sexual activity, or poorly maintained erection despite initially good response.
• Agreeable to attempt sexual intercourse at least 4 times per month for duration of study without being under the influence of alcohol or recreational drugs
• Morning total testosterone level over 300ng/dL

Exclusion Criteria (ED):

• Nerve-injury related ED (/spinal cord injury, severe lumbosacral disorder (radiculopathy, spinal stenosis) or other neurological disease affecting erectile functions (e.g, multiple sclerosis, alzheimer's disease, parkinsons disease, amyotrophic lateral sclerosis)
• Untreated hypogonadism (morning total testosterone <300 ng/dL) or on androgen deprivation therapy in the last 12 months
• Predominately psychogenic ED based upon expert clinician opinion
• Peyronie's disease, palpable plaque or curvature/penile anatomic abnormality that affects penetrative intercourse to any degree
• History of non-superficial penile surgery (e.g, penile prosthesis, penectomy, plication, grafting)
• History of penile injury or trauma (e.g, priapism, penile fracture)
• Use of intracavernosal injection for ED within the last year
• If diabetic, HbA1c 8% or higher within the past 12 months
• Known corporal veno-occlusive dysfunction based on prior Doppler penile ultrasound
• Current tobacco smoker, or has smoked in the past year
• Poorly controlled hyperlipidemia
• Poorly controlled hypertension
• Severe cardiac disease or history of myocardial infarction
• History of psychiatric disorder including bipolar disorder, current moderate or severe depression
• Patients currently using SSRI or psychotropic medication
• Severe ED based on IIEF-EF (score 10 or below)
• Current acute prostatitis

Chronic Pelvic Pain Syndrome Group:

Inclusion Criteria (CPPS): (all of the following)

• Adult males ≥18 years old
• Chronic pelvic pain not explained by concurrent urinary tract infections. urine)
• Willing to do PFPT

Exclusion criteria (CPPS):

• Nerve-injury related pelvic pain (history of /spinal cord injury, severe lumbosacral disorder (radiculopathy, spinal stenosis) or other neurological disease affecting pain in the pelvic region(Multiple sclerosis, Alzheimer's, Parkinsons disease)
• Acute prostatitis or any acute infection of the pelvic region
• History of pelvic trauma

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Treatment

Study locations

United States · 1 center

• Cleveland Clinic Foundation — Cleveland

Identifiers

NCT: NCT05868668 · 23-103

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗